Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

11/12/24 10:32:10 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LXRX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 LEXICON PHARMACEUTICALS INC COMMON STOCK Cusip #528872302 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #528872302 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 49,864,692 Item 6: 0 Item 7: 49,867,042 Item 8: 0 Item 9: 49,867,042 Item 11: 13.794% Item 12: HC Cusip #528872302 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 49,867,042 Item 8: 0 Item 9: 49,867,042 Item 11: 13.794% Item 12: IN Item 1(a). Name of Issuer: LEXICON PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 2445 TECHNOLOGY FOREST BLVD., SUITE 1100 THE WOODLANDS, TX 77381 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 528872302 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 49,867,042 (b) Percent of Class: 13.794% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 49,867,042 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of LEXICON PHARMACEUTICALS INC. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of LEXICON PHARMACEUTICALS INC, amounted to 22,105,910 shares or 6.115% of the total outstanding COMMON STOCK at September 30, 2024. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company * BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of LEXICON PHARMACEUTICALS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $LXRX alert in real time by email

Date

Price Target

Rating

Analyst

6/17/2024

$10.00

Buy

H.C. Wainwright

4/30/2024

$5.00

Outperform

Leerink Partners

3/7/2023

$3.00

Hold

Jefferies

8/12/2022

$10.00

Overweight

Piper Sandler

Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for $LXRX

$LXRX Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target

Lexicon Pharmaceuticals Receives Dec. 20, 2024 PDUFA Goal Date For Sotagliflozin Type 1 Diabetes NDA Resubmission

$LXRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

SEC Form SC 13G filed by Lexicon Pharmaceuticals Inc.

$LXRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by SVP, Regulatory & QA Corrigan Brian

SEC Form 3 filed by new insider Corrigan Brian

New insider Siren, L.L.C. claimed ownership of 38,918,903 shares (SEC Form 3)

$LXRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$LXRX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$LXRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$LXRX Press Releases

Fastest customizable press release news feed in the world

$LXRX Leadership Updates

Live Leadership Updates

H.C. Wainwright initiated coverage on Lexicon Pharma with a new price target

Leerink Partners initiated coverage on Lexicon Pharma with a new price target

Jefferies initiated coverage on Lexicon Pharma with a new price target

FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

Coats Lonnel bought $94,797 worth of shares (90,000 units at $1.05), increasing direct ownership by 11% to 914,359 units (SEC Form 4)

Coats Lonnel bought $10,100 worth of shares (10,000 units at $1.01), increasing direct ownership by 1% to 824,359 units (SEC Form 4)

Debbane Raymond bought $1,103,957 worth of shares (1,000,000 units at $1.10), increasing direct ownership by 293% to 1,340,847 units (SEC Form 4)

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

$LXRX Financials

Live finance-specific insights

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

$LXRX SEC Filings

SEC Form 10-Q filed by Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Lexicon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

Recent Analyst Ratings for
$LXRX

$LXRX
Market Insights

$LXRX
Large Ownership Changes

$LXRX
Insider Trading

$LXRX
Analyst Ratings

$LXRX
FDA approvals

$LXRX
Insider Purchases

$LXRX
Press Releases

$LXRX
Leadership Updates

$LXRX
Financials

$LXRX
SEC Filings